Reacción a "A vaccine to prevent pancreatic cancer in high-risk individuals is safe and induces long-lasting immune responses in a phase 1 trial"

This study involves vaccinating people with a genetic predisposition to pancreatic cancer using mutations of the KRAS oncogene, which is very frequently mutated in pancreatic cancer. The conclusion is that it is possible to elicit specific immune responses against these mutations. The study involved only 20 subjects and did not demonstrate efficacy, although there appeared to be fewer cystic lesions—a sign of probable malignancy—following vaccination.

This is an interesting immunogenicity study, but it is too early to know whether or not it will actually prevent cases of pancreatic cancer in genetically predisposed families.